Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy

Prolonged exposure of breast carcinoma cells in vitro to tamoxifen results in tamoxifen resistance. Tamoxifen‐resistant cells express increased HER‐2/neu mRNA and protein. The objective of this study was to determine whether patients with metastatic or locally advanced breast carcinoma who have negative serum HER‐2/neu status at the initiation of first‐line hormone therapy with letrozole or tamoxifen convert to positive serum HER‐2/neu status at the time of disease progression and to determine whether serum HER‐2/neu conversion to positive status is associated with response to therapy and overall survival.

[1]  Mitch Dowsett,et al.  Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.

[2]  W. Carney,et al.  Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Nicholson,et al.  Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.

[4]  J. Garcia-conde,et al.  NH2-terminal Truncated HER-2 Protein but not Full-Length Receptor Is Associated with Nodal Metastasis in Human Breast Cancer , 2002 .

[5]  J. Slingerland,et al.  Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells* , 2001, The Journal of Biological Chemistry.

[6]  I. Ellis,et al.  Phosphorylation of ERK1/2 mitogen‐activated protein kinase is associated with poor response to anti‐hormonal therapy and decreased patient survival in clinical breast cancer , 2001, International journal of cancer.

[7]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Clarke,et al.  Cellular and molecular pharmacology of antiestrogen action and resistance. , 2001, Pharmacological reviews.

[9]  D. Chan,et al.  Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. , 2001, Anticancer research.

[10]  A. Lenferink,et al.  Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. , 2000, Cancer research.

[11]  A. Dnistrian,et al.  Monitoring Therapy by Serum HER-2/Neu , 2000, The International journal of biological markers.

[12]  R. Nicholson,et al.  Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer , 2000, British Journal of Cancer.

[13]  J. Robertson,et al.  Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. , 1999, Endocrine-related cancer.

[14]  H. W. van den Berg,et al.  The anti-proliferative effects of tyrosine kinase inhibitors towards tamoxifen-sensitive and tamoxifen-resistant human breast cancer cell lines in relation to the expression of epidermal growth factor receptors (EGF-R) and the inhibition of EGF-R tyrosine kinase. , 1999, Cancer letters.

[15]  L. Murphy,et al.  Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. , 1998, Cancer research.

[16]  S. Kharbanda,et al.  Constitutive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis , 1997, Oncogene.

[17]  J. Robertson,et al.  Oestrogen receptor: a stable phenotype in breast cancer. , 1996, British Journal of Cancer.

[18]  J. Robertson.  84. Oestrogen receptor — a stable phenotype in breast cancer , 1995 .

[19]  P. Briand,et al.  Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1. , 1994, Cancer research.

[20]  R. Clarke,et al.  MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. , 1993, Cancer research.

[21]  M. Lynch,et al.  Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75-1 human breast cancer cell line. , 1992, British Journal of Cancer.

[22]  W. Carney,et al.  Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. , 1989, Oncogene.

[23]  W. McGuire,et al.  Measurement of steroid hormone receptors in breast cancer patients on tamoxifen , 2004, Breast Cancer Research and Treatment.

[24]  W. Carney.  The Emerging Role of Monitoring Serum HER-2/neu Oncoprotein Levels in Women with Metastatic Breast Cancer , 2003 .

[25]  J. Garcia-conde,et al.  NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Rakesh Kumar,et al.  Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo1. , 2000, Endocrinology.

[27]  Ji-ping Wang,et al.  Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. , 2000, Endocrinology.

[28]  J. Bruix,et al.  Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[29]  R. Wittes,et al.  Manual of Adult and Paediatric Medical Oncology , 1987, UICC International Union Against Cancer.